drugset / Trial / NCT05740488
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases. The primary endpoint is PFS and the second endpoints are pCR, rPFS, PSA response, pain score, number and extent of bone metastases.
Timeline
- Start
- 2022-01-07
- Primary completion
- 2025-04
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Sr | Unknown | 100 mbq | Intravenous |
| Subject | 89Sr | Unknown | 150 mbq | Intravenous |
| Subject | Apalutamide | Small molecule | 240 mg | Oral |